MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that its leadership team will present at three upcoming industry and investor events: the 2025 Cell & Gene Meeting on the Mesa, Chardan’s 9th Annual Genetic Medicines Conference, and the 2025 Maxim Growth Summit.
“These industry and investor meetings provide an excellent forum to share specifically how Ocugen is advancing toward our goal of three BLAs in the next three years,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “We are excited to share our contribution toward bringing a new generation of gene therapies to market and engage with potential partners to join us on our journey.”
At Meeting on the Mesa, Abhi Gupta, Executive Vice President, Commercial and Business Development, will deliver a company presentation, while Dr. Musunuri will join panel discussions at both the Chardan and Maxim conferences. In addition to these public sessions, Ocugen executives will hold one-on-one meetings with investors and industry stakeholders.
Event schedule:
- Cell & Gene Meeting on the Mesa – Company Presentation: Today, Monday, October 6, 2025, at 4:00 p.m. MST, Ballroom G, Arizona Biltmore, Phoenix, AZ
- Chardan’s 9th Annual Genetic Medicines Conference – Panel: In Vivo Gene Therapy: Breaking into Competitive Ophthalmic Indications: Tuesday, October 21, 2025, 9:30–10:10 a.m. EDT, Reid Salon, Lotte Palace Hotel, New York, NY
- 2025 Maxim Growth Summit – Panel: Ophthalmology Panel—A Vision of Innovation: Wednesday, October 22, 2025, 3:00–4:00 p.m. EDT, Hard Rock Hotel, New York, NY
The company said its participation underscores its focus on advancing gene therapies in ophthalmology and beyond, while engaging with investors on its broader business and clinical development strategy.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.